China Biopharmaceutical: TQ-A3334 and TQA3605 Granted Breakthrough Therapy Designation by CDE

China Biopharmaceutical announced on the Hong Kong Stock Exchange that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed two National Class 1 innovative drugs, TQ-A3334 "Toll-like receptor 7 agonist" and TQA3605 "core protein allosteric modulator," both of which have been included in the Breakthrough Therapy Designation program by the Center for Drug Evaluation of China's National Medical Products Administration. The two innovative drugs respectively address two major unmet needs in the treatment of chronic hepatitis B: functional cure and low-level viremia.